| scholarly article | Q13442814 |
| P50 | author | Denis Hochstrasser | Q54889429 |
| Ruth Nussenzweig | Q2177773 | ||
| P2093 | author name string | Schneider M | |
| Tiercy JM | |||
| Rose K | |||
| Loutan L | |||
| Oliveira GA | |||
| Nardin EH | |||
| Calvo-Calle JM | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| malaria vaccine | Q6741353 | ||
| Plasmodium falciparum | Q311383 | ||
| P304 | page(s) | 481-489 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Journal of Immunology | Q3521441 |
| P1476 | title | A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types | |
| P478 | volume | 166 |
| Q35073970 | A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. |
| Q35301295 | A candidate dual vaccine against influenza and noroviruses |
| Q41058932 | A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge |
| Q34261339 | A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts |
| Q89985509 | AJP001, a novel helper T-cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine |
| Q28744149 | Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults |
| Q33830488 | An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses |
| Q64916679 | Blockade of Human α7 Nicotinic Acetylcholine Receptor by α-Conotoxin ImI Dendrimer: Insight from Computational Simulations. |
| Q37223839 | Cellular effector mechanisms against Plasmodium liver stages |
| Q33756504 | Chelation of Ca²⁺ ions by a peptide from the repeat region of the Plasmodium falciparum circumsporozoite protein |
| Q27006858 | Delivery of host cell-directed therapeutics for intracellular pathogen clearance |
| Q38820422 | Dendrimer-based nanocarriers: a versatile platform for drug delivery |
| Q37886750 | Dendrimers and miktoarm polymers based multivalent nanocarriers for efficient and targeted drug delivery. |
| Q46831913 | Designing and modeling of complex DNA vaccine based on tropomyosin protein of Boophilus genus tick |
| Q40470069 | Differential antibody responses to Plasmodium falciparum-derived B-cell epitopes induced by diepitope multiple antigen peptides (MAP) containing different T-cell epitopes. |
| Q43583421 | Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques |
| Q37075435 | Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod |
| Q39201869 | Epitope mapping of Brugia malayi ALT-2 and the development of a multi-epitope vaccine for lymphatic filariasis |
| Q40197794 | Expression and immunogenicity of the Plasmodium falciparum circumsporozoite protein: the role of GPI signal sequence |
| Q36737531 | HLA-DR: molecular insights and vaccine design |
| Q47445263 | Human dendritic cells pulsed with specific lipopeptides stimulate autologous antigen-specific T cells without the addition of exogenous maturation factors. |
| Q30497914 | Imaging effector functions of human cytotoxic CD4+ T cells specific for Plasmodium falciparum circumsporozoite protein. |
| Q28972540 | Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands |
| Q98627418 | Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein |
| Q50863204 | Immunoprophylaxis of multi-antigen peptide (MAP) vaccine for human lymphatic filariasis. |
| Q34517062 | Improved method for predicting linear B-cell epitopes |
| Q90592477 | In silico design of a T-cell epitope vaccine candidate for parasitic helminth infection |
| Q40735997 | Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses |
| Q45059557 | Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity |
| Q34749774 | Lipopeptide vaccines--yesterday, today, and tomorrow |
| Q92867203 | Lipoproteins: Structure, Function, Biosynthesis |
| Q48026407 | Major histocompatibility complex and T cell interactions of a universal T cell epitope from Plasmodium falciparum circumsporozoite protein |
| Q35630416 | Malaria vaccine developments |
| Q92052807 | Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics |
| Q35093445 | Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults |
| Q91327492 | Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population |
| Q33290869 | Multivalency - a way to enhance binding avidities and bioactivity - preliminary applications to EPO. |
| Q40491174 | Novel lipopeptides of ESAT-6 induce strong protective immunity against Mycobacterium tuberculosis: Routes of immunization and TLR agonists critically impact vaccine's efficacy |
| Q92976912 | Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform |
| Q36273059 | Peptide dendrimers. |
| Q34692321 | Peptide dendrimers: applications and synthesis |
| Q38779839 | Peptide-Decorated Dendrimers and Their Bioapplications |
| Q34462075 | Peptide-based subunit vaccines against pre-erythrocytic stages of malaria parasites |
| Q40205403 | Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. |
| Q33318466 | Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein |
| Q36726849 | Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses |
| Q34571421 | Plasmodium falciparum variability and immune evasion proceed from antigenicity of consensus sequences from DBL6ε; generalization to all DBL from VAR2CSA. |
| Q34125960 | Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. |
| Q44106022 | Prediction and identification of B cell epitopes derived from EWS/FLI-l fusion protein of Ewing's sarcoma |
| Q36378330 | Priming of CD4+ T cells and development of CD4+ T cell memory; lessons for malaria |
| Q34521010 | Progress and challenges for malaria vaccines |
| Q35161394 | Progress towards achieving new vaccine and vaccination goals |
| Q27487800 | Rapid Determination of HLA B*07 Ligands from the West Nile Virus NY99 Genome |
| Q45950594 | Rational design and immunogenicity of liposome-based diepitope constructs: application to synthetic oligosaccharides mimicking the Shigella flexneri 2a O-antigen. |
| Q42754531 | Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial |
| Q39571564 | Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. |
| Q36083687 | Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope |
| Q45350056 | Solid phase oxime ligations for the iterative synthesis of polypeptide conjugates |
| Q27652547 | Structural and immunological analysis of circumsporozoite protein peptides: a further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine |
| Q59354284 | T Cell Immunity To Enterovirus 71 Infection In Humans And Implications For Vaccine Development |
| Q34400322 | TLR-based immune adjuvants. |
| Q34228659 | Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection |
| Q24250252 | Vaccines for preventing malaria |
| Q24244317 | Vaccines for preventing malaria (pre-erythrocytic) |
| Q81369539 | Versatile and efficient synthesis of protein-polysaccharide conjugate vaccines using aminooxy reagents and oxime chemistry |
| Q24244392 | WITHDRAWN: Vaccines for preventing malaria |
| Q33587443 | Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model |
Search more.